Literature DB >> 12555678

Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice.

Takayuki Sato1, Naoto Ishii, Kazuko Murata, Kazu Kikuchi, Satoshi Nakagawa, Lishomwa C Ndhlovu, Kazuo Sugamura.   

Abstract

Langerhans cells (LC) represent the dominant antigen-presenting cells (APC) in the epidermis and thus play an important role in cutaneous immune responses to approaching pathogens. These responses are mediated by several costimulatory molecules after antigenic challenge. OX40 ligand (OX40L), a member of TNF superfamily, is expressed on several APC such as splenic dendritic cells (DC) and activated B cells. This molecule has been reported to provide potent costimulation in APC-T cell interactions upon binding to its cognate receptor, OX40, on activated T cells. Little is known, however, regarding OX40L expression and function on LC. In the present study, we report the expression of both OX40L and OX40 on differentiated LC derived from draining lymph nodes in the FITC-sensitized mice. During contact hypersensitivity responses, OX40L-deficient mice demonstrated a significant reduction in both hapten-induced ear swelling and hapten-specific T cell responses despite intact migratory responses. Conversely, these responses were markedly increased in two different OX40L-transgenic strains with variations in OX40L overexpression. In the LC-induced MLR, OX40L-deficient and OX40L-overexpressing LC were capable of reducing and elevating the responses of allogeneic CD4+ T cells, respectively. Thus the requirement of OX40L during the antigen presentation function of LC in T cell priming is here demonstrated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555678     DOI: 10.1002/1521-4141(200211)32:11<3326::AID-IMMU3326>3.0.CO;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 2.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 3.  The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Authors:  Amy E Moran; Magdalena Kovacsovics-Bankowski; Andrew D Weinberg
Journal:  Curr Opin Immunol       Date:  2013-02-14       Impact factor: 7.486

Review 4.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 5.  B cell regulation of anti-tumor immune response.

Authors:  Yu Zhang; Richard Morgan; Eckhard R Podack; Joseph Rosenblatt
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 6.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

7.  The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways.

Authors:  Xiang Xiao; Xiaomin Shi; Yihui Fan; Chenglin Wu; Xiaolong Zhang; Laurie Minze; Wentao Liu; Rafik M Ghobrial; Peixiang Lan; Xian Chang Li
Journal:  Immunity       Date:  2016-06-14       Impact factor: 31.745

8.  OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.

Authors:  Ichiyo Shibahara; Ryuta Saito; Rong Zhang; Masashi Chonan; Takuhiro Shoji; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Masahiko Kanehira; Toshiaki Kikuchi; Takanori So; Takashi Watanabe; Hiroaki Takahashi; Erina Iwabuchi; Yuetsu Tanaka; Yukiko Shibahara; Hironobu Sasano; Naoto Ishii; Teiji Tominaga
Journal:  Mol Cancer       Date:  2015-02-15       Impact factor: 27.401

Review 9.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

10.  OX40 signaling favors the induction of T(H)9 cells and airway inflammation.

Authors:  Xiang Xiao; Savithri Balasubramanian; Wentao Liu; Xiufeng Chu; Haibin Wang; Elizabeth J Taparowsky; Yang-Xin Fu; Yongwon Choi; Matthew C Walsh; Xian Chang Li
Journal:  Nat Immunol       Date:  2012-07-29       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.